Medtronic PLC $MDT Shares Acquired by Wealthfront Advisers LLC

Wealthfront Advisers LLC boosted its holdings in Medtronic PLC (NYSE:MDT) by 14.7% during the 3rd quarter, Holdings Channel reports. The fund owned 86,543 shares of the medical technology company’s stock after acquiring an additional 11,104 shares during the quarter. Wealthfront Advisers LLC’s holdings in Medtronic were worth $8,242,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently added to or reduced their stakes in the company. AXQ Capital LP grew its position in Medtronic by 25.6% in the 2nd quarter. AXQ Capital LP now owns 9,890 shares of the medical technology company’s stock worth $862,000 after purchasing an additional 2,013 shares during the last quarter. UMB Bank n.a. grew its position in Medtronic by 65.8% during the third quarter. UMB Bank n.a. now owns 138,278 shares of the medical technology company’s stock worth $13,170,000 after buying an additional 54,898 shares in the last quarter. Principal Financial Group Inc. grew its position in Medtronic by 17.2% during the third quarter. Principal Financial Group Inc. now owns 1,656,155 shares of the medical technology company’s stock worth $157,732,000 after buying an additional 242,910 shares in the last quarter. Willis Investment Counsel increased its stake in Medtronic by 5.0% during the third quarter. Willis Investment Counsel now owns 401,868 shares of the medical technology company’s stock valued at $38,274,000 after acquiring an additional 19,192 shares during the period. Finally, Sector Gamma AS raised its holdings in Medtronic by 35.5% in the 3rd quarter. Sector Gamma AS now owns 303,441 shares of the medical technology company’s stock valued at $28,900,000 after acquiring an additional 79,441 shares in the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Medtronic Trading Down 0.3%

Shares of MDT stock opened at $101.07 on Thursday. The company has a quick ratio of 1.80, a current ratio of 2.42 and a debt-to-equity ratio of 0.57. The company has a market capitalization of $129.58 billion, a P/E ratio of 27.24, a P/E/G ratio of 2.67 and a beta of 0.71. Medtronic PLC has a 12-month low of $79.55 and a 12-month high of $106.33. The firm has a 50-day moving average price of $99.34 and a 200 day moving average price of $96.32.

Medtronic (NYSE:MDT) last posted its quarterly earnings data on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share for the quarter, topping the consensus estimate of $1.31 by $0.05. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The company had revenue of $8.96 billion during the quarter, compared to analyst estimates of $8.86 billion. During the same quarter last year, the business posted $1.26 earnings per share. The company’s revenue was up 6.6% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Research analysts forecast that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, January 16th. Stockholders of record on Friday, December 26th were issued a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a dividend yield of 2.8%. The ex-dividend date was Friday, December 26th. Medtronic’s dividend payout ratio is presently 76.55%.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the company. TD Cowen reissued a “buy” rating on shares of Medtronic in a report on Friday, November 14th. Wall Street Zen upgraded shares of Medtronic from a “hold” rating to a “buy” rating in a research note on Friday, January 23rd. Citigroup started coverage on shares of Medtronic in a research note on Tuesday, February 3rd. They issued a “buy” rating and a $117.00 price objective for the company. Truist Financial lowered their target price on shares of Medtronic from $110.00 to $107.00 and set a “hold” rating on the stock in a research note on Thursday, December 18th. Finally, Sanford C. Bernstein increased their price target on shares of Medtronic from $111.00 to $112.00 and gave the stock an “outperform” rating in a research report on Friday, January 9th. Sixteen equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $111.21.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).